Small cell lung cancer: Difference between revisions

Jump to navigation Jump to search
Line 60: Line 60:


Regardless of stage, the current prognosis for patients with SCLC is unsatisfactory even though considerable improvements in diagnosis and therapy have been made during the past 10 to 15 years.
Regardless of stage, the current prognosis for patients with SCLC is unsatisfactory even though considerable improvements in diagnosis and therapy have been made during the past 10 to 15 years.
==Pathological Findings==
[http://www.peir.net Images courtesy of Professor Peter Anderson DVM PhD and published with permission © PEIR, University of Alabama at Birmingham, Department of Pathology]
<div align="left">
<gallery heights="175" widths="175">
image:Oat cell carcinoma.jpg|Histopathologic image of oat cell carcinoma of the lung. Gross fixed tissue opened bronchus at hilum showing tumor close-up.
Image:SCC2.jpg|Lung: Carcinoma: Gross natural color good photo of left upper lobe neoplasm extending into mediastinal pleura and surrounding portion of aorta node metastasis easily seen small cell carcinoma (unusual spindle cell areas)
</gallery>
</div>


==Related Chapters==
==Related Chapters==

Revision as of 16:34, 9 December 2011

For patient information click here

Template:DiseaseDisorder infobox

Small Cell Carcinoma of the Lung Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Small Cell Carcinoma of the Lung from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Radiation Therapy

Surgery

Prevention

Future or Investigational Therapies

Case Studies

Case #1

Small cell lung cancer On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Small cell lung cancer

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Small cell lung cancer

CDC on Small cell lung cancer

Small cell lung cancer in the news

Blogs on Small cell lung cancer

Directions to Hospitals Treating Small cell carcinoma of the lung

Risk calculators and risk factors for Small cell lung cancer

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Synonyms and related keywords: Oat Cell Carcinoma, Reserve Cell Carcinoma, Round Cell Carcinoma, Small Cell Lung Carcinoma, Small Cell Lung Cancer


Overview

Historical Perspective

Pathophysiology

Epidemiology and Demographics

Risk Factors

Screening

Causes

Differentiating Small cell carcinoma of the lung from other diseases

Natural history, Complications, & Prognosis

Diagnosis

History and Symptoms | Physical Examination | Laboratory tests | Electrocardiogram | X Rays | CT | MRI Echocardiography or Ultrasound | Other images | Alternative diagnostics

Treatment

Medical therapy | Surgical options | Primary prevention | Secondary prevention | Financial costs | Future therapies

References

Limited-stage disease

At the time of diagnosis, approximately 30% of patients with SCLC will have tumor confined to the hemithorax of origin, the mediastinum, or the supraclavicular lymph nodes. These patients are designated as having limited-stage disease, and most 2-year disease-free survivors come from this group. In limited-stage disease, median survival of 16 to 24 months with current forms of treatment can reasonably be expected. A small proportion of patients with limited-stage disease may benefit from surgery with or without adjuvant chemotherapy; these patients have an even better prognosis.

Extensive-stage disease

Patients with tumors that have spread beyond the supraclavicular areas are said to have extensive-stage disease and have a worse prognosis than patients with limited-stage disease. Median survival of 6 to 12 months is reported with currently available therapy, but long-term disease-free survival is rare.

Prognostic factors

The pretreatment prognostic factors that consistently predict for prolonged survival include good performance status, female gender, and limited-stage disease. Patients with involvement of the central nervous system or liver at the time of diagnosis have a significantly worse outcome. In general, patients who are confined to bed tolerate aggressive forms of treatment poorly, have increased morbidity, and rarely attain 2-year disease-free survival; however, patients with poor performance status can often derive significant palliative benefit and prolongation of survival from treatment.

Regardless of stage, the current prognosis for patients with SCLC is unsatisfactory even though considerable improvements in diagnosis and therapy have been made during the past 10 to 15 years.

Related Chapters

External links



Template:WikiDoc Sources